Loading...
Loading...
Shares of Savient Pharmaceuticals Inc
SVNT just popped on rumors it could be the subject of a takeover rumor.
At this time, it is not known who the potential acquirer could be, but a
Reuters article posted yesterday indicated that Abbott
ABT, Pfizer
PFE or Amgen
AMGN could be potential suitors.
Shares of SVNT are up 58 cents to $20.86, a gain of 2.86%.
Savient is a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in